Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7444-7453

  Sterman, Daniel H ^a,b,d   Recio, Adriana ^c   Vachani, Anil ^a,b   Sun, Jing ^a   Cheung, Lumei ^a   DeLong, Peter ^a,b   Amin, Kunjlata M ^a,d   Litzky, Leslie A ^d   Wilson, James M ^d   Kaiser, Larry R ^a,d   Albelda, Steven M ^a,b  

^a Thoracic Oncology Research Laboratory   (United States)

^b Allergy   (United States)

^c Abramson Family Cancer Institute   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MALE; METABOLIC ACTIVATION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RELIABILITY; SUICIDE GENE THERAPY; TUMOR CELL LINE;

ADENOVIRIDAE; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GANCICLOVIR; GENE THERAPY; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SIMPLEXVIRUS; THYMIDINE KINASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 27144497008     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0405     Document Type: Article

References (52)

1. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 1995;2:702-9.
2. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994;56:203-9.
3. Elshami AA, Saavedra A, Zhang HB, et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996;3:85-92.
4. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53:5274-83.
5. Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994;54:6228-34.
6. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997;33:1005-16.
7. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;82:297-300.
8. Culver KW, Ram Z, Wallbridge, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
9. Ram Z, Culver KW, Walbridge, Blaese RM, Oldfield EH. In situ retroviral-mediated gene transfer for the treatment Of brain tumors in rats. Cancer Res 1993;53:83-8.
10. Rainov N. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11:2389-401.
11. Smythe WR, Hwang HC, Amin KM, et al. Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Ann Surg 1995;222:78-86.
12. Smythe WR, Hwang HC, Amin KM, et al. Recombinant adenovirus transfer of the HSV-thymidine kinase gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994;54:2055-9.
13. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995;13:7-16.
14. Esandi MC, van Someren GD, Vincent AJ, et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 1997;4:280-7.
15. Izquierdo M, Martin V, De Felipe P, et al. Human malignant brain tumor response to herpes simplex thymidine kinase/ganciclovir gene therapy. Gene Ther 1996;3:491-5.
16. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol 2003;65:279-89.
17. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003;7:851-8.
18. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther 2003;14:227-41.
19. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76.
20. Hasenburg A, Tong XW, Rojas-Martinez A, et al. Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 2000;7:839-44.
21. Sung MW, Yeh HC, Thung SN, et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. Mol Ther 2001;4:182-91.
22. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995;107:332-44S.
23. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, The Dana-Farber Cancer Institute and Brigham and Women's Hospital Experience Over Two Decades, 1965-1985. J Clin Oncol 1988;6:147-53.
24. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993;103:373-6S.
25. Robinson BW, Robinson C, Lake RA. Localised spontaneous regression in mesothelioma: possible immunological mechanism. Lung Cancer 2001;32:197-201.
26. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
27. Sugarbaker DJ, Flores R, Jaklitsch M, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
28. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase 1 clinical trial in malignant mesothelioma. Hum Gene Ther 1998;9:1083-92.
29. Molnar-Kimber KL, Sterman DH, Chang M, et al. Humoral and cellular immune responses induced by adenoviral-based gene therapy for localized malignancy: results of a phase 1 clinical trial for malignant mesothelioma. Hum Gene Ther 1998;9:2121-33.
30. Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther 2000;7:1511-8.
31. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-43.
32. Lanuti M, Gao GP, Force SD, et al. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum Gene Ther 1999;10:463-75.
33. Treat J, Kaiser LR, Sterman DH, et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Hum Gene Ther 1996;7:2047-57.
34. Bénard F, Sterman DH, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorine-18-deoxyglucose positron emission tomography. Chest 1998;114:713-22.
35. Bénard F, Sterman DH, Smith RJ, et al. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-5.
36. Nanni C, Castellucci P, Farsad M, et al. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm 2004;19:149-54.
37. Goldman MJ, Litzky LA, Englehardt JF, Wilson JM. Transfer of the CFTR gene to the lung of non-human primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther 1995;6:839-51.
38. Sheibani K, Stroup RM. Immunopathologyof malignant mesothelioma. Pathology 1996;4:191-212.
39. Elshami A, Kucharczuk J, Zhang H, et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the HSV-thymidine kinase gene. Hum Gene Ther 1996;7:141-8.
40. Kruse CA, Roper MD, Kleinschmidt-DeMasters BK, et al. Purified herpes simplex thymidine kinase Retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther 1997;4:118-28.
41. Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999;10:1239-49.
42. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.
43. Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2000;2:524-30.
44. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide gene therapy. Lancet 1997;349:2-3.
45. Todryk S, Melcher A, Hardwick N, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999;163:1398-408.
46. Chen SH, Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995;92:2577-81.
47. Drozdzik M, Qian C, Xie X, et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J Hepatol 2000;32:279-86.
48. Castleden SA, Chong H, Garcia-Ribas I, et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther 1997;8:2087-102.
49. Majumdar AS, Zolotorev, Samuel S, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther 2000;7:1086-99.
50. Odaka M, Sterman DH, Wiewrodt W, et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-β gene therapy is attributable to induction of systemic immunity. Cancer Res 2001;61:6201-12.
51. Wold WS, Tollefson M. Adenovirus E3 proteins: 14.7K, RID, and gp19K inhibit immune-induced cell death; adenovirus death protein promotes cell death. Semin Virol 1998;8:515-23.
52. Katabi M, Yuan S, Chan H, et al. The nonapoptotic pathway mediating thymidine kinase/ganciclovir toxicity is reduced by signal from adenovirus type 5 early region 4. Mol Ther 2002;5:170-6.